HUTCHMED (China) Ltd FRESCO-2 Data at ESMO Call Transcript
Good evening, afternoon, and morning. Welcome to HUTCHMED Conference Call and Webcast. (Operator Instructions) Please be advised that this call will be recorded. I'll turn the call over to your first speaker today, Dr. Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED. Please go ahead, sir.
()- -
Thank you. Welcome, everyone. This is the FRESCO-2 Phase III trial conference call. A couple of hours ago, we just presented the Phase III top line results at ESMO. I understand the presentation time was the most friendly for folks in the U.S. So we are privileged today to have the steering committee of the study members on the call to give another presentation and also a panel discussion.
Following that, we'll have the Q&A. So on the screen is the HUTCHMED development portfolio. HUTCHMED is dedicated to innovation and bringing our innovations to patients worldwide. Today's focus is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |